SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

This study is testing a drug called SKB264 (an antibody-drug combination) alone or with other therapies in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to previous treatments. **You may be eligible if...** - You are between 18 and 75 years old with confirmed NSCLC - Your tumor has no EGFR or ALK mutations (cohorts 1 and 2), or has an EGFR mutation and has failed prior EGFR-targeted therapy (cohort 3) - You have at least one measurable tumor on imaging - Your organ function and performance status are within acceptable ranges - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your cancer has small cell components or has spread to the brainstem or spinal cord - You have active brain metastases - You have serious heart disease, uncontrolled lung disease, or significant fluid buildup around the lungs or heart - You have active hepatitis B, hepatitis C, HIV, or tuberculosis - You are pregnant or breastfeeding - You have had an organ or stem cell transplant from a donor Talk to your doctor to see if this trial is right for you.